10x Genomics, Inc. Class A Common Stock
TXG10x Genomics, Inc. Class A (TXG) is a biotechnology company specializing in genomics and single-cell analysis solutions. It develops and commercializes advanced instruments and reagents that enable researchers to analyze biological systems at high resolution, facilitating breakthroughs in areas such as cancer, immunology, and genetics. The company's technologies are used in academic, clinical, and industrial research to accelerate understanding of complex biological processes.
Company News
ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions ...
The global spatial genomics and transcriptomics market is projected to grow from USD 0.60 billion in 2025 to USD 1.90 billion by 2035 at a 12.23% CAGR. Growth is driven by increased adoption of AI-powered spatial biology technologies, precision medicine initiatives, and high-resolution molecular profiling in oncology and translational research. N...
Quantedge Capital added 212,600 shares of 10x Genomics in Q1 2026 for approximately $4.25 million, signaling investor confidence in the company. The stock has surged 116% over the past year, significantly outperforming the S&P 500's 26% gain. Despite being unprofitable, 10x Genomics showed improving fundamentals with 9% adjusted revenue growth, 7...
The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic an...
Cathie Wood's Ark Invest made surprisingly few purchases last week, buying shares in only three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Despite significant declines from their highs, Wood sees value in these growth-stage companies across design software, biotech, and genomics sectors.
